File Download
  Patent History
  • Application
    PC T/CN2009001117 2009-10-09
  • Publication
    WO 2010040277 2010-04-15

published patent: CADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER

TitleCADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER
Priority Date2008-10-09 US 12/104038P
Inventors
Issue Date2010
Citation
WO Published patent application WO 2010040277. World Intellectual Property Organization (WIPO), PatentScope, 2010 How to Cite?
AbstractCompositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH 17 overexpression based on the detection of CDH 17 or the use of CDH 17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and /or monitoring liver cancers using the expressing of CDH 17 involve detecting and/or quantitating the CDH 17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. The presence of CDH 17 molecule in liver tissues denotes the incidence of liver cancer. The methods can be used to detect either soluble or truncated forms of CDH 17 by using antibodies specific for the unique regions spanning domains 1 and 2 (D1-D2) of the truncated and secreted CDH 17. Methods for treating liver cancers using CDH 17 as a target and of sensitizing cells with aberrant expression of CDH 17 have also been developed. The methods include suppression or knockdown of the expression of CDH 17 by administering an effective amount of a CDH 17 inhibitor. The suppression or knockdown of CDH 17 reduces in size liver tumors derived from tumor cells that exhibit an increased expression of CDH 17 and renders liver tumor cells more sensitive to certain chemotherapeutic drugs, such as Taxol, Epirubicin, and Carboplatin, and p53-based gene therapy.
Persistent Identifierhttp://hdl.handle.net/10722/177143
References

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:39:12Z-
dc.date.available2012-11-30T08:39:12Z-
dc.date.issued2010-
dc.identifier.citationWO Published patent application WO 2010040277. World Intellectual Property Organization (WIPO), PatentScope, 2010en_HK
dc.identifier.urihttp://hdl.handle.net/10722/177143-
dc.description.abstractCompositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH 17 overexpression based on the detection of CDH 17 or the use of CDH 17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and /or monitoring liver cancers using the expressing of CDH 17 involve detecting and/or quantitating the CDH 17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. The presence of CDH 17 molecule in liver tissues denotes the incidence of liver cancer. The methods can be used to detect either soluble or truncated forms of CDH 17 by using antibodies specific for the unique regions spanning domains 1 and 2 (D1-D2) of the truncated and secreted CDH 17. Methods for treating liver cancers using CDH 17 as a target and of sensitizing cells with aberrant expression of CDH 17 have also been developed. The methods include suppression or knockdown of the expression of CDH 17 by administering an effective amount of a CDH 17 inhibitor. The suppression or knockdown of CDH 17 reduces in size liver tumors derived from tumor cells that exhibit an increased expression of CDH 17 and renders liver tumor cells more sensitive to certain chemotherapeutic drugs, such as Taxol, Epirubicin, and Carboplatin, and p53-based gene therapy.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleCADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCERen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorLuk, JMCen_HK
dc.contributor.inventorLee, Puiyue Nikkien_HK
dc.contributor.inventorLiu, Lingxiaoen_HK
dc.contributor.inventorPoon, RTPen_HK
dc.contributor.inventorFan, STen_HK
patents.identifier.applicationPC T/CN2009001117en_HK
patents.description.assigneeUNIV HONG KONG [CN]; LUK MOONCHING JOHN [CN]; LEE PUIYUE NIKKI [CN]; LIU LINGXIAO [CN]; POON TUNGPING RONNIE [CN]; FAN SHEUNGTAT [CN]en_HK
patents.description.countryWorld Intellectual Property Organization (WIPO)en_HK
patents.date.publication2010-04-15en_HK
dc.relation.referencesUS 2007065859 (A1) 2007-03-22en_HK
dc.relation.referencesWO 9957149 (A3) 2000-03-02en_HK
dc.relation.referencesWO 9957149 (A2) 1999-11-11en_HK
dc.relation.referencesUS 2005002919 (A1) 2005-01-06en_HK
dc.relation.referencesWO 2009012773 (A1) 2009-01-29en_HK
dc.relation.referencesXP 002591718en_HK
dc.relation.referencesXP 004470763en_HK
dc.relation.referencesXP 008145831en_HK
dc.relation.referencesXP 008145829en_HK
dc.relation.referencesXP 008145832en_HK
dc.relation.referencesXP 004512473en_HK
dc.relation.referencesXP 019427607en_HK
dc.relation.referencesXP 019464776en_HK
dc.relation.referencesXP 008145837en_HK
patents.identifier.hkutechidSurg-2008-00285-8-
patents.date.application2009-10-09en_HK
patents.date.priority2008-10-09 US 12/104038Pen_HK
patents.description.ccWOen_HK
patents.identifier.publicationWO 2010040277en_HK
patents.relation.familyCN 102483414 (A) 2012-05-30en_HK
patents.relation.familyEP 2342568 (A1) 2011-07-13en_HK
patents.relation.familyUS 2010092978 (A1) 2010-04-15en_HK
patents.relation.familyWO 2010040277 (A1) 2010-04-15en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats